share_log

Avenue Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Fortress Biotech, Inc.

SEC announcement ·  Apr 18 04:10
Summary by Futu AI
Fortress Biotech, Inc., reported a completed transaction involving the acquisition of 413,507 shares of common stock in Avenue Therapeutics, Inc. (ATXI) on April 16, 2024. The shares were granted at no cost, as indicated by a transaction price of $0.00. Following this transaction, Fortress Biotech's direct holdings in Avenue Therapeutics increased to a total of 3,547,393 shares. The nature of the transaction was described as a grant, award, or other acquisition, according to the transaction code 'A'. This event reflects a significant increase in Fortress Biotech's stake in the pharmaceutical company.
Fortress Biotech, Inc., reported a completed transaction involving the acquisition of 413,507 shares of common stock in Avenue Therapeutics, Inc. (ATXI) on April 16, 2024. The shares were granted at no cost, as indicated by a transaction price of $0.00. Following this transaction, Fortress Biotech's direct holdings in Avenue Therapeutics increased to a total of 3,547,393 shares. The nature of the transaction was described as a grant, award, or other acquisition, according to the transaction code 'A'. This event reflects a significant increase in Fortress Biotech's stake in the pharmaceutical company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.